BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Zeltiq Files Legal Action and Preliminary Injuction Request Against Marco Hallerbach, MD


10/10/2012 7:22:22 AM

PLEASANTON, Calif.--(BUSINESS WIRE)-- ZELTIQ Aesthetics, Inc. (ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced it filed a lawsuit in the United States District Court for the Middle District of Florida, Tampa Division, against Marco Hallerbach, MD, and Dr. Hallerbach & Associates, Inc., for false advertising, false designation of origin, unfair competition, trademark infringement, and unfair and deceptive trade practices. In addition, ZELTIQ simultaneously filed a motion requesting a preliminary injunction to cease Dr. Hallerbach’s misleading advertising and prevent him from further use of ZELTIQ’s trademarks.

Dr. Hallerbach, doing business as Dr. Hallerbach and Associates, Inc., operates a “cosmetic medicine and weight management” clinic under the name of Get Your Shape Back. The clinic is representing to prospective customers and patients that its purported Cryolipolysis treatments are the authentic, unique, patented FDA-cleared CoolSculpting treatments developed by ZELTIQ. In its complaint, ZELTIQ alleges that Dr. Hallerbach’s attempts to pass off his services as authentic CoolSculpting treatments have resulted in actual customer confusion and dissatisfaction with the sham procedure. ZELTIQ further alleges that in addition to baiting potential patients into his own clinic, Dr. Hallerbach also offers these services to various spas in the area. Dr. Hallerbach has ignored cease and desist demands from ZELTIQ and continues to offer the purported Cryolipolysis treatments.

ZELTIQ is the exclusive licensee of Cryolipolysis, the patented technology behind the aesthetic procedure marketed as CoolSculpting®. Cryolipolysis is the non-invasive cooling of adipose tissue to induce lipolysis – the breaking down of fat cells – to reduce body fat without damage to other tissues.

“ZELTIQ prides itself on a reputation based on clinically proven safety and efficacy, and we will vigorously protect that reputation from copycat devices not cleared by the FDA,” said Sergio Garcia, ZELTIQ Senior Vice President, General Counsel and Corporate Secretary. “We urge consumers to beware of misleading and deceptive advertising and to seek CoolSculpting treatments only from authorized physician providers within the elite network of CoolSculpting Centers.”

About ZELTIQ Aesthetics, Inc.

ZELTIQ® Aesthetics, Inc. (ZLTQ) is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ’s first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise.

Contact:

MEDIA CONTACT:

GOLD PR for ZELTIQ

Shari Gold, 714-251-0375

or

INVESTOR RELATIONS:

ZELTIQ

Mark Foley, 925-474-2500

President and CEO

or

The Ruth Group for ZELTIQ

Nick Laudico / Amy Glynn

646-536-7030 / 7023



Read at BioSpace.com

Zeltiq
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES